This pathological transition and the extent to which antimicrobial leakage occurs and causes inflammatory and other maladaptive sequelae of obesity may also be influenced by host factors, including genetics. In the proposed study, we will directly test the Thrifty Mirobiome Hypothesis by performing detailed genomic and functional assessment of gut microbial communities in intensively phenotyped and genotyped human subjects before and after intentional manipulation of the gut microbiome. To address this hypothesis, we will enroll three age-and sex-matched groups from the Old Order Amish: (i) 50 obese subjects (BMI > 30 kg/m2) with one or more dysmetabolic manifestations (malignant obesity), (ii) 50 obese subjects (BMI > 30 kg/m2) without any dysmetabolic manifestations (benign obesity), and (iii) 50 nonobese subjects (BMI < 25 kg/m2) without any features of the metabolic syndrome and characterize the architecture of the gut microbiota from the subjects enrolled in this study by high-throughput sequencing of 16S rRNA genes. These studies will provide a deeper understanding of the role of gut microbes in terms of 'who's there?', 'what are they doing?', and 'how are they influencing host energy homeostasis, obesity and its metabolic complications?' II.
DATA QUALITY:
Sequencing quality control: Through the use of automated reports, the LIMS at the Genomic Resource Center (GRC) at the Institute for Genome Sciences enables staff to monitor data quality trends in real time and quickly identify problems. Because each sample, plate, and well is tracked through each of the pipelines, and quality control tests are performed at key steps, problems that occur can be rapidly isolated and the cause identified, tested, and resolved. These reports are monitored daily by the GRC Directors and provide data about sequencing success, read length, and sequence quality by sequencer instrument, sequencing run, project, library, operator, and date. When the GRC detects a potential problem in one of the sequencing pipelines, these reports are used to identify potential causes. Usually the cause can be narrowed to a small number of possibilities within minutes. Consistency is essential to the efficient operation of a high-throughput genomics laboratory. To ensure this consistency, all activities within the GRC are based on tested and approved Standard Operating Procedures. These SOPs are written in a standardized format and include detailed instructions for the performance of each laboratory or bioinformatics protocol. New or modified SOPs undergo review and scientific approval by the assigned reviewer and are approved for publication to the IGS internal web site and use by the GRC Directors. At minimum, each SOP is reviewed annually by the GRC Scientific Director.
454 pyrosequencing of barcoded 16S rRNA genes: The V1-V2 regions of 16S rRNA genes were/will be sequenced using Roche/454 FLX and Titanium chemistries. To pass quality control a sequence read (a) included a perfect match to the sequence tag (barcode) and the 16S rRNA gene primer; (b) was at least 300 bp in length; (c) had no more than two undetermined bases; and (d) had a least 60% match to a previously determined 16S rRNA gene sequence after alignment with
NAST. An average ~4,000 reads were/will be generated per sample. The depth of coverage for each community is sufficient to detect taxa that constitute ~0.1% of the community.
Metadata quality control:
Old Order Amish subjects are recruited by trained personnel at the Amish Research Clinic in Lancaster, PA. Pertinent medical history, height, weight, and waist circumference is obtained using established protocols and quality assurance methods. Fasting blood is drawn and serum glucose and lipid levels are measured (Quest Diagnostics, Horsham, PA). Vitamins and supplements were discontinued for at least 14 days prior to two fecal collections, which were obtained 3 to 24 months apart from each research subject. The fecal sample is immediately suspended in RNALater for subsequent processing and 16S sequence analysis.
We will comprehensively capture metadata associated with our microbiome samples to support comparisons between these samples based on attributes such as patient disease history, collection procedures or site of infection. Unfortunately, a universally recognized standard describing microbiome metadata has yet to emerge. To ameliorate this we will operate in close collaboration with the larger metagenomic community on development of this standard. Currently the best contender for a standard metadata description is the Minimum Information about Metagenome Sequence (MIMS) which has been crafted by the Genome Standards Consortium (Field et al., 2008) . We will work to promote coordination for metadata description through the GSC, as well as the to-be-funded Data Analysis and Coordination Center (DACC) for the HMP; we consider these bodies to be the most significant focal points for data standards and integration.
III. DATA ANALYSIS AND PUBLICATION PLANS:
Following trimming of primer and barcode sequences, binning by sample, and removal of reads containing ambiguous bases, 16S sequencing data will be analyzed using both phylogenetic binning and operational taxonomical unit (OTU)-based approaches. The former approach allows us to generate, for each sample, the ratio of the two dominant phyla in the gut microbiome (Bacteroides:Firmicutes) and also to identify family-and genus-level taxa whose prevalence in the human gut may correlate with obesity. Using our OTU-based analysis, we will generate trees showing the relatedness of samples to each other and also to calculate a measure of the bacterial diversity present in each sample (Shannon index). A major focus of our analysis will be to examine potential correlations between Bacteroides:Firmicutes ratios or Shannon indices and characteristics of the human host, including the existence of single nucleotide polymorphisms (SNPs) associated with obesity.
A manuscript describing the results of these analyses is currently in preparation and we expect to submit it in the fall of 2010.
IV. DATA RELEASE PLAN:
Release of clinical data to a controlled access site specified by the NIH. We will work with the HMP Program Officers and other HMP awardees to establish the appropriate guidelines for release of clinical data to a controlled access site specified by the NIH. We are aware of the potential sensitivities in making clinical data available and we are willing to participate in any discussions related to this topic to ensure that we strike the appropriate balance between respecting patient confidentiality and making any relevant clinical data that will aid in interpretation of metagenomic datasets available to the investigators who need access to this information.
Release of sequence read and trace data or the equivalent for new technologies.
We will deposit 16S rRNA gene sequences in GenBank, using the standard batch upload procedure. One common issue with environmental samples of 16S rRNA is that metadata about the environment is lost, which can limit reusability of the sequences in further analyses by other investigators. We will address this issue by including within the "source" feature an "isolation_source" descriptor that stores the string "Homo sapiens fecal sample", along with a coded patient id, health status and sample collection data in a comma-delimited format. This will allow automated parsing tools to assign each sequence to the correct sample. Deposition in GenBank will also ensure inclusion of the sequences in the Ribosomal Database Project at http://rdp.cme.msu.edu, which automatically compiles sequences from GenBank on a monthly basis.
In collaboration with HMP Program Officers, we will develop a plan for release of whole microbial community shotgun sequencing data generated under this project. We would suggest that a plan be devised that would make this data available to the scientific community as quickly as possible (e.g., weekly downloads of sequences to the Trace Archive or Short Read Archive, as appropriate, and monthly downloads of assembled data), while at the same time respecting the priorities of the investigators carrying out the work to perform an initial analysis of these data. A combined assembly of all datasets will be submitted to GenBank as a Whole Genome Shotgun project, containing all contiguous sequences. This central page will contain links to an assembly of each individual fecal/biopsy microbiome dataset (deposited as distinct projects) and the raw sequencing reads (deposited in the NCBI Short Read Archive). Deposited sequences will be annotated according to site of sampling (fecal samples/location of biopsies, etc.); DNA extraction method, sequencing method, predicted functions (COG, KEGG, InterPro assignments), predicted organism, and de-identified subject metadata.
Release of any other type of data to characterize the microbiome being studies. The Amish Obesity Project Database (AOPD) repository will be a short-term resting place for all data generated in this project, and will be hosted and maintained at UMSOM. Upon advice from the HMP Program Officers, this data resource will be moved to the to-be created HMP DACC, for longer term maintenance and better public accessibility, when appropriate. Release of metadata associated with sequence traces or other types of data. We will work with the HMP Program Officers and other HMP awardees to establish the appropriate guidelines for release of metadata. We can deposit metadata in the Short Read Archive, or house this information on our project website. We would recommend that all HMP awardees work with the HMP Program Officers to develop a set of standards related to metadata to facilitate comparisons between datasets.
Release of analysis performed by the awardee. It is our intention to use scientific publications as the primary means of releasing the analyses that will be performed in the course of these studies. 
